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PMH63
TREND AND GEOGRAPHIC VARIATIONS IN THE LENGTH OF
STAY FOR SCHIZOPHRENIA IN THE UNITED STATES
Sun SX1, Liu GG1, Luo X2, Fu AZ1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;
2Duke University Medical Center, Durham, NC, USA
OBJECTIVES: To assess the national trend and regional varia-
tions in the length of stay (LOS) and medical practices for schiz-
ophrenia in the United States. METHODS: Schizophrenia
inpatient care records were selected from the 1988 through 2000
National Inpatient Sample of Hospital Care Utilization Project
(HCUP), a database that approximates a 20% sample of all US
community hospitals. Using hospital and discharge sampling
weights, national level estimates were produced to demonstrate
the changes and patterns in LOS, medical practices, and associ-
ated demographic and clinical characteristics. RESULTS: The
national average LOS for schizophrenia was found to have
decreased from 16.22 days in year 1988 to 11.16 days in year
2000. Signiﬁcant drop in LOS was observed from 1994 to 1998,
but in all other years the changes were very small. The LOS
varied substantially across geographical areas. In year 2000, the
lowest LOS was 8.75 days in the Midwest, whereas in the North-
east LOS was nearly doubled at 16.18 days, and topped the
national level. This difference was also accompanied by a sharp
difference in medical practice between the two regions, that in
the Midwest, individual psychotherapy (ICD-9-CM procedure
code 9439) and electroshock therapy (code 9427) were the two
most commonly used principal procedures, accounting for 27%
and 15% respectively, whereas in the Northeast, psychiatric drug
therapy (code 9425) was most common (38%), followed by
other counseling (code 9449, 14%). In addition, there existed
some regional differences in demographic and clinical charac-
teristics. CONCLUSIONS: LOS for schizophrenia patients has
decreased considerably from year 1988 to 2000 and differed 
signiﬁcantly between different regions. These ﬁndings carry
important policy implications regarding the relative efﬁciency,
appropriateness and quality of hospital care in treating schizo-
phrenia patients. Further studies are warranted to assess the
patient health outcomes associated with the varied treatment
patterns.
PMH64
MISDIAGNOSIS OF BIPOLAR DISORDER AS 
UNIPOLAR DEPRESSION
Stensland MD1, deLay N1, Ciaglia M2,Viswanathan S3
1Eli Lilly and Company, Indianapolis, IN, USA; 2ZS Associates, Evanston,
IL, USA; 3ZS Associates, Boston, MA, USA
Bipolar disorder is frequently misdiagnosed as unipolar depres-
sion, in part, because of its episodic and cyclical nature. When
a patient presents with symptoms of depression, a history of
bipolar disorder precludes a unipolar depression diagnosis.
OBJECTIVE: The objective of this study was to examine the rate
that bipolar patients are misdiagnosed with unipolar depression
in current practice. METHODS: To examine patterns of diag-
nosis, the PharMetrics Integrated Outcomes Database of adju-
dicated medical and pharmaceutical claims for over 3 million
patients from 11 U.S. health plans was utilized. In this database,
3679 patients had two claims with ICD-9 diagnostic codes for
bipolar disorder (296.0, 296.1, 296.4–296.8) that were not
accompanied by a unipolar depression diagnostic code, age
between 10 and 64, and 1 year of continuous eligibility prior to
and following the initial bipolar diagnosis claim. RESULTS: In
the 12 months prior to their initial bipolar diagnosis, 14% of
patients had at least two claims for unipolar depression. In the
12 months following the initial bipolar diagnostic claim 32%
had at least two unipolar depression claims. When examining
only patients who were diagnosed with bipolar disorder during
an inpatients hospital stay, 47% were diagnosed with unipolar
depression in the following 12 months. CONCLUSION: A dis-
concertingly high proportion of bipolar patients were diagnosed
with unipolar depression following their initial bipolar diag-
noses. These results suggest that greater physician education 
is needed regarding bipolar disorder and the importance of
obtaining a history when patients present with symptoms of
depression.
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SECOND SSRIS SWITCHING AND DISCONTINUATION AFTER
FLUOXETINE INITIAL THERAPY
Shaya F1, Mullins CD1, Meng F1,Wang J1, Harrison DJ2
1University of Maryland, Baltimore, MD, USA; 2Pﬁzer, Inc, New York,
NY, USA
OBJECTIVES: This study compares switching and discontinua-
tion rates for patients who had already switched from ﬂuoxetine
to other branded selective serotonin reuptake inhibitors (SSRIs).
METHODS: Retrospective analysis of claims in an administra-
tive database from January 1, 1999 to June 30, 2002. Claims for
patients on ﬂuoxetine who switched to sertraline, paroxetine or
citalopram were analyzed to compare rates of discontinuation or
second switch to another SSRI. We used Cox proportional
models and life table survival curves. Deﬁnition of switching or
discontinuation was based on SSRI reﬁll within 15 days or 2 days
supply. RESULTS: Paroxetine patients (N = 217) were signiﬁ-
cantly more likely to switch (HR = 1.47, p = 0.033) than ser-
traline patients (N = 227). The likelihood of switching (HR =
0.98, p = 0.917) was not signiﬁcantly different for patients on
citalopram (N = 291) than on sertraline. Patients were as likely
to discontinue when on sertraline (N = 324), paroxetine (N =
293) or citalopram (N = 437). Average number of distinct drugs
(p = 0.0005) and average number of claims (p = 0.0006) were
signiﬁcant predictor of discontinuation, while age, gender and
co-payment were not. CONCLUSIONS: Patients on ﬂuoxetine
who had switched to paroxetine were signiﬁcantly more likely
to switch again than those who had switched to sertraline. The
likelihood of discontinuation was similar among patients on 
sertraline, paroxetine or citalopram.
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COMPARISON OF FIRST REFILL RATES AMONG BRANDED
SSRI USERS
Mullins CD1, Shaya FT1, Meng F1,Wang J1, Bron M2
1University of Maryland, Baltimore, MD, USA; 2Pﬁzer, Inc, New York,
NY, USA
OBJECTIVES: Prior research documents that discontinuation
rates among selective serotonin reuptake inhibitor (SSRI) users
are high, but little is known about the likelihood of reﬁlling at
least one prescription. This study compares rates of ﬁrst reﬁlls
across SSRIs that remain on patent. METHODS: This retro-
spective cohort study used an administrative database from
January 1, 1999 to June 30, 2002. Patients were followed up to
6 months after the ﬁrst branded SSRIs. “Reﬁll” was deﬁned as
reﬁlling the ﬁrst prescription for SSRIs of interest within 15 days
or 1.5 times days supply. Logistic regression and sensitivity
analyses examined the impact of age, gender, and co-payment as
covariates. RESULTS: Based on descriptive analyses, sertraline,
patients (N = 5590; 54.70% reﬁll; p = 0.0001) or citalopram
patients (N = 4124; 54.49% reﬁll; p = 0.0008) were more likely
to have a reﬁll than paroxetine patients (N = 5201; 50.99%
reﬁll). These results were consistent with the logistic regressions
where covariates were signiﬁcant at the p < 0.10 but not the p
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< 0.05 level. CONCLUSIONS: The likelihood of reﬁlling an
SSRI varies by the speciﬁc SSRI and may vary by age, gender,
and copayment amount. Patients are more likely to reﬁll the ﬁrst
prescriptions for sertraline or citalopram than for paroxetine.
PMH67
DEPRESSION DIAGNOSIS IN PRIMARY CARE VISITS NOT FOR
MENTAL HEALTH REASONS 
Singer ME, Propper VH
Case Western Reserve University, Cleveland, OH, USA
OBJECTIVE: To examine factors associated with diagnosis of
depression at a primary care visit for reasons unrelated to depres-
sion. METHODS: We used the 1998–2000 National Ambula-
tory Medical Care Survey for ofﬁce-based physician visits. We
included visits to their primary care physician for patients with
no indication of prior episodes of depression. We excluded
patients under 15 years old and visits where the major reason
for the visit was for mental health or social problems. We created
a multivariate logistic regression model to examine which factors
were associated with a depression diagnosis. Study variables
included: age, race, sex, geographic region, urban setting,
payment source, time spent with physician, new patient, HMO
status, capitated visit, and major reason for the visit. RESULTS:
There were 18,612 patients meeting study criteria, of whom
11,365 (61%) were female, 2,037 (11%) black, 1,940 (10%)
were under age 25 and 5,629 (30%) were at least 65 years old.
A total of 234(1.5%) patients received a depression diagnosis.
Multivariate analysis showed that younger (age 15–24; OR =
0.486, p = 0.0177) and older patients (age 65+; OR = 0.517, p
< 0.0001) were less likely to receive a depression diagnosis.
Factors associated with increased likelihood of depression diag-
nosis: female (OR = 1.81, p < 0.0001), self-pay (OR = 1.64, p =
0.329), and major reason for visit a chronic problem, both
routine (OR = 2.24, p < 0.0001) and ﬂareup (OR = 1.58, p =
0.0349). There were non-signiﬁcant trends towards reduced rate
of diagnosis in blacks (OR = 0.645, p = 0.0811) and visits related
to surgery/injury(OR = 0.343, p = .0620), and towards higher
rates in the West(OR = 1.38, p = 0.0847). There was no associ-
ation between diagnosis of depression and urban setting, new
patient, capitated visit, HMO enrollment. Association of time
spent with the physician and depression diagnosis was marginal,
though statistically signiﬁcant. CONCLUSIONS: When seeing
their primary care physician for reasons unrelated to mental
health or social problems, patients who were age 25–64, female,
self-pay or visiting for a chronic illness were substantially more
likely to be diagnosed with depression.
PMH68
TRENDS IN PHARMACOLOGIC TREATMENT FOR PATIENTS
WITH BIPOLAR: 1992–2002
Cooper LM, Zhao Z, Zhu B
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: Assess trends in pharmacologic treatment for
patients with bipolar disorder. METHODS: A large claims data-
base of insured individuals from October 1992 to September
2002 was analyzed to identify patients diagnosed with bipolar
disorder (ICD9-CM: 296.4x–296.8x). Treatment regimens were
examined for six-classes of psychotropics (antidepressants,
mood-stabilizers, atypical and typical antipsychotics, anxiolytics
and hypnotics). RESULTS: Of 13,407 patients, the percent
untreated remained stable around 10% over the 10-year period.
Among treated patients, about 65% received mood stabilizers
and/or antidepressants. The two agents most frequently used
were valproate (39.7%) and olanzapine (24.2%) in 2002.
Overall, mood stabilizers increased slightly from 59.5% to
64.2%, and atypical antipsychotics increased from 4.5% to
45.1% usage. Antidepressants and anxiolytics remained stable
at around 65% and 50% respectively, although the products
chosen shifted with new market introductions. Typical antipsy-
chotics decreased from 34.5% to12.4%, and hypnotics
decreased from 13.2% to around 7% usage. CONCLUSIONS:
Although about two-thirds of patients with bipolar illness receive
mood stabilizers, there continues to be opportunity for improve-
ment in pharmacotherapy. It is also important to understand out-
comes associated with changing treatment patterns for bipolar
patients.
PMH69
PATTERNS OF PHARMACOLOGIC TREATMENT FOR
PATIENTS WITH BIPOLAR DISORDER
Zhu B, Zhao Z, Cooper LM
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: Assess recent pharmacologic treatment patterns
for patients with bipolar disorder. METHODS: A large claims
database of insured individuals from October 1998 to Septem-
ber 2002 was analyzed to identify patients diagnosed with
bipolar disorder (ICD9-CM: 296.4x–296.8x). Treatment regi-
mens were examined for six-classes of psychotropics (antide-
pressants, mood-stabilizers, atypical and typical antipsychotics,
anxiolytics and hypnotics) during the year post-diagnosis. Dif-
ferences in medication use among sub-types of bipolar were
compared. RESULTS: Of 6373 patients (56.4% female, mean
age 49.2 years), 19.4% were depressed, 14.2% manic, 21.2%
mixed, and 45.1% other episodes; 9.1% didn’t receive psy-
chotropic treatment. Among treated patients, 66.0% received
antidepressants, 64.0% mood-stabilizers, 48.2% anxiolytics,
and 42.1% atypical antipsychotics. Valproate (40.3%) and olan-
zapine (22.0%) were top two most commonly prescribed psy-
chotropics. Only 22.7% received single-class therapy, 44.2%
received ≥3 classes and 19.8% received ≥5 classes of psy-
chotropics. Among depressed patients, 76.7% received antide-
pressants, 59.2% received mood-stabilizers and 39.9% received
atypical antipsychotics versus 45.4%, 71.2% and 54.4% in
manic patients, respectively. Surprisingly, 52.3% of depressed
patients received anxiolytics—the highest percentage among all
sub-types of bipolar patients. CONCLUSIONS: Pharmacother-
apy for bipolar patients is complex. Nearly half of bipolar
patients were treated with3 classes of psychotropics. Depressed
patients were more likely to receive antidepressants and anxi-
olytics but less likely to receive mood-stabilizers.
PMH70
PHARMACOLOGIC TREATMENT PATTERNS FOR 
BIPOLAR DISORDER
deLay N1, Stensland MD1,Viswanathan S2, Ciaglia M3
1Eli Lilly and Company, Indianapolis, IN, USA; 2ZS Associates, Boston,
MA, USA; 3ZS Associates, Evanston, IL, USA
OBJECTIVE: To examine managed-care treatment patterns for
patients diagnosed with bipolar disorder. METHODS: We exam-
ined the PharMetrics Integrated Outcomes Database of adjudi-
cated medical and pharmaceutical claims for over 3 million
patients from 11 U.S. health plans. We identiﬁed 4,455 bipolar
patients based on the following criteria: two claims with ICD-9-
CM diagnosis for bipolar disorder (296.0, 296.1, 296.4–296.8),
age between 10 and 64, and 1 year of continuous eligibility prior
to and following the initial bipolar diagnosis with claims begin-
ning January 1, 1999. RESULTS: Of the 4455 bipolar patients,
80% (3555) received medication-based treatment in a 13-month
window around the index diagnosis (12 months post and 1
month pre). A total of 38% of bipolar patients used 4 or more
medications during the 13 months. On average each patient
